Physician profile
Abel Eugene Biesman
NPI 1881115442
$4,951.29
in general payments reported to CMS, 2019-2025
28 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $28.47 · 2021: $58.31 · 2022: $724 · 2023: $1,131 · 2024: $1,597 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,990.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,664.93 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $740.30 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $489.23 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $417.49 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $400.50 | 2022-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $271.07 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.74 | 2022-2024 | Jardiance |
| Exact Sciences Corporation | $144.19 | 2024-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $136.95 | 2019 | |
| Inspire Medical Systems, INC. | $104.12 | 2023 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.15 | 2022-2023 | Xifaxan |
| Pfizer INC. | $54.22 | 2024-2025 | |
| Pacira Therapeutics, INC. | $35.94 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.43 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.11 | 2024-2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $24.42 | 2024 | Fanapt |
| Alvogen INC | $22.41 | 2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $19.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.88 | 2023 | Quviviq |
| Astellas Pharma US INC | $18.47 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $17.96 | 2025 | |
| Shield Therapeutics INC | $17.54 | 2023 | Accrufer |
| Ucb, INC. | $16.27 | 2021 | |
| Axsome Therapeutics, INC. | $15.22 | 2025 | Auvelity |
| Amarin Pharma, INC. | $14.02 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.66 | 2019 | |
| Merck Sharp & Dohme LLC | $13.30 | 2020 | |
| Linus Health, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Biesman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.